{
    "nct_id": "NCT05512390",
    "official_title": "A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies",
    "inclusion_criteria": "* For dose escalation (Part 1) only: Participants with documented diagnosis of B-cell malignancies including those with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment, as per the protocol.\n* For the relapsed or refractory diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) dose expansion cohorts (Part 2) only: Participants with documented diagnosis of one of the B-cell malignancies noted in the protocol with histology based on criteria established by the WHO, and measurable disease requiring treatment, as per the protocol.\n* Laboratory values meeting the criteria noted in the protocol.\n* For participants previously treated with a CD19-targeting therapy (eg, CD19 monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD19-targeting therapy must be collected.\n* Participant must have measurable disease, as defined by the 2014 Lugano Classification.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known active central nervous system (CNS) disease, or primary CNS lymphoma.\n* Known active infection or clinically significant uncontrolled conditions as per the protocol.\n* Eastern Cooperative Oncology Group (ECOG) performance status >= 2.",
    "miscellaneous_criteria": ""
}